Ontology highlight
ABSTRACT: Background
Combination therapy with the B-Raf inhibitor, dabrafenib, and the MEK inhibitor, trametinib (DT) is commonly used to treat patients with B-Raf proto-oncogene, serine/threonine kinase V600E (BRAF V600E)-mutated non-small cell lung cancer (NSCLC). However, the mechanisms through which cancer develops DT resistance are unclear. Here, we investigated new mechanisms underlying acquired DT-resistant NSCLC with the BRAF V600E mutation.Methods
We compared genomic signatures before and after DT treatment in patients with NSCLC.Results
Two of four patients treated with DT developed carcinomatous pleuritis within 3 months. Target DNA sequencing and quantitative polymerase chain reaction (PCR) analyses revealed the increased expression level of cyclin-d
SUBMITTER: Hirai N
PROVIDER: S-EPMC8512466 | biostudies-literature | 2021 Sep
REPOSITORIES: biostudies-literature